Anupam Kumar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anupam Kumar has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bharat Aggarwal
Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1901 East Road, 4SCR3.1006, Houston, TX 77030, USA
1 shared publication - Bokyung Sung
Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA
1 shared publication - Dihua Yu
Department of Molecular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
1 shared publication - Jia Xu
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, 10029, USA
1 shared publication - Kapil Mehta
The University of Texas MD Anderson Cancer Center
1 shared publication - Santosh Kumar
Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, 1901 East Road, 4SCR3.1006, Houston, TX 77030, USA
1 shared publication
Latest Publications
- Open Access
- 6 January 2012
- Published by Springer Nature in Breast Cancer Research
- Vol. 14 (1) , R4
Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells
Introduction: The expression of proinflammatory protein tissue transglutaminase 2 (TG2) is frequently upregulated in multiple cancer cell types. However, the exact role of TG2 in cancer cells is not well-understood. We recently initiated studies to determine the significance of TG2 in cancer cells and observed that sustained expression of TG2 resulted in epithelial-to-mesenchymal transition (EMT) and promoted cancer stem cell (CSC) traits in mammary epithelial cells. These results suggested that TG2 could serve as a promising therapeutic target for overcoming chemoresistance and inhibiting metastatic spread of cancer cells. Methods: Using various mutant constructs, we analyzed the activity of TG2 that is essential for promoting the EMT-CSC phenotype. Results: Our results suggest that catalytically inactive TG2 (TG2-C277S) is as effective as wild-type TG2 (TG2-WT) in inducing the EMT-CSC in mammary epithelial cells. In contrast, overexpression of a GTP-binding-deficient mutant (TG2-R580A) was completely incompetent in this regard. Moreover, TG2-dependent activation of the proinflammatory transcription factor NF-κB is deemed essential for promoting the EMT-CSC phenotype in mammary epithelial cells. Conclusions: Our results suggest that the transamidation activity of TG2 is not essential for promoting its oncogenic functions and provide a strong rationale for developing small-molecule inhibitors to block GTP-binding pockets of TG2. Such inhibitors may have great potential for inhibiting the TG2-regulated pathways, reversing drug resistance and inhibiting the metastasis of cancer cells.
- 6 January 2012
- Published by Springer Nature in Breast Cancer Research
- Vol. 14 (1) , R4
Open AccessEvidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells
Introduction: The expression of proinflammatory protein tissue transglutaminase 2 (TG2) is frequently upregulated in multiple cancer cell types. However, the exact role of TG2 in cancer cells is not well-understood. We recently initiated studies to determine the significance of TG2 in cancer cells and observed that sustained expression of TG2 resulted in epithelial-to-mesenchymal transition (EMT) and promoted cancer stem cell (CSC) traits in mammary epithelial cells. These results suggested that TG2 could serve as a promising therapeutic target for overcoming chemoresistance and inhibiting metastatic spread of cancer cells. Methods: Using various mutant constructs, we analyzed the activity of TG2 that is essential for promoting the EMT-CSC phenotype. Results: Our results suggest that catalytically inactive TG2 (TG2-C277S) is as effective as wild-type TG2 (TG2-WT) in inducing the EMT-CSC in mammary epithelial cells. In contrast, overexpression of a GTP-binding-deficient mutant (TG2-R580A) was completely incompetent in this regard. Moreover, TG2-dependent activation of the proinflammatory transcription factor NF-κB is deemed essential for promoting the EMT-CSC phenotype in mammary epithelial cells. Conclusions: Our results suggest that the transamidation activity of TG2 is not essential for promoting its oncogenic functions and provide a strong rationale for developing small-molecule inhibitors to block GTP-binding pockets of TG2. Such inhibitors may have great potential for inhibiting the TG2-regulated pathways, reversing drug resistance and inhibiting the metastasis of cancer cells.